Core Viewpoint - Fuhong Hanlin (02696) shares rose over 4% following the approval of two biosimilars, BILDYOS and BILPREVDA, by the UK Medicines and Healthcare products Regulatory Agency, covering all indications of the original drugs in the UK [1] Group 1: Company Developments - Fuhong Hanlin's stock increased by 4.53%, reaching 64.6 HKD, with a trading volume of 79.4842 million HKD [1] - The UK regulatory approval allows Fuhong Hanlin to commercialize BILDYOS and BILPREVDA, which are part of a broader agreement with Organon for exclusive commercialization rights outside of China [1] - Boyu Capital has increased its stake in Fuhong Hanlin, acquiring 262,500 shares and 80,000 shares on November 6 and November 10, respectively, raising its holding from 5.84% to 7% [1] Group 2: Financial Transactions - Boyu Capital previously invested 21.2673 million HKD to increase its stake from 4.89% to 5.15% on June 18, crossing the 5% threshold for reporting [1]
港股异动 | 复宏汉霖(02696)现涨超4% 地舒单抗BILDYOS和BILPREVDA获英...